耐多药/利福平耐药结核病化学治疗年度进展2022  

Annual progress of chemotherapy of multidrug/rifampicin-resistant tuberculosis in 2022

作　　者：于佳佳 唐神结[1] Yu Jiajia;Tang Shenjie(Beijing Chest Hospital,Capital Medical University,Beijing Tuberculosis and Thoracic Tumor Research Institute,Tuberculosis Clinical Medical Center,Beijing 101149,China)

机构地区：[1]首都医科大学附属北京胸科医院结核病临床医学中心、北京市结核病胸部肿瘤研究所,北京101149

出　　处：《中华结核和呼吸杂志》2023年第1期62-66,共5页Chinese Journal of Tuberculosis and Respiratory Diseases

基　　金：北京市临床重点专科项目(20201214)。

摘　　要：目前,我国耐多药/利福平耐药结核病(MDR/RR-TB)的发病人数居世界第四位,防治形势依然十分严峻。化学治疗作为MDR/RR-TB治疗的最重要手段,国内外同道在2022年度对此进行了一系列研究和探索。化学治疗新药delpazolid、sutezolid、telacebec及我国自主研发的抗结核新药吡法齐明、舒达吡啶、JBD0131等尚处于临床试验阶段。对贝达喹啉、利奈唑胺、德拉马尼、普托马尼等已上市药物的有效性、安全性、耐受性、不良反应和耐药问题等进行了广泛的研究。同时,各国学者对以新药为核心的不同化学治疗新方案也进行了较为深入的探讨。本文就2021年10月至2022年9月的以上进展作一综述。At present,the number of cases with multidrug/rifampicin-resistant tuberculosis(MDR/RR-TB)in China ranks fourth in the world,and the prevention and control situation is still serious.Chemotherapy,as the most important treatment for MDR/RR-TB,was studied and explored by domestic and foreign researchers in 2022.New chemotherapeutic drugs such as delpazolid,sutezolid,telacebec and independently developed anti-tuberculosis drugs such as pyrifazimine,sudapyridine and JBD0131 are still in clinical trials.The efficacy,safety,tolerability,adverse reactions and drug resistance of bedaquiline,linezolid,delamanid and pretomanid have been studied extensively.Meanwhile,different new chemotherapy regimens centered on new drugs have been explored in-depth by international scholars.In this article,we reviewed the progress of chemotherapy of multidrug/rifampicin-resistant tuberculosis from October 2021 to September.

关 键 词：抗结核新药 耐多药 化学治疗 利奈唑胺 耐药问题 治疗新药 不良反应 临床试验阶段 

分 类 号：R978.3[医药卫生—药品]